HCA
PCRX icon

Harbor Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Harbor Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Sell
109
-75
-41% -$1.77K ﹤0.01% 1185
2026
Q1 		$4K Buy
184
+4
+2% +$89 ﹤0.01% 1161
2025
Q4 		$5K Sell
180
-3
-2% -$71 ﹤0.01% 1149
2025
Q3 		$5K Buy
+183
New +$4.5K ﹤0.01% 1175

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return

Harbor Capital Advisors's PCRX Position: Q2 2026 in Review

Harbor Capital Advisors reduced its Pacira BioSciences (PCRX) stake by 41% in Q2 2026, selling an estimated $1.77K and leaving 109 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

Harbor Capital Advisors first reported a position in PCRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $5K in Q4 2025. 118 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Harbor Capital Advisors held 109 shares of Pacira BioSciences worth $3K as of Q2 2026.
  • Harbor Capital Advisors sold 75 Pacira BioSciences shares in Q2 2026, an estimated $1.77K.
  • Pacira BioSciences made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #1185 holding.
  • Harbor Capital Advisors first reported a position in Pacira BioSciences in Q3 2025 and has held it in 4 quarters since.
  • Harbor Capital Advisors's Pacira BioSciences position peaked at $5K in Q4 2025.
  • 118 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.